An oral fluoropyrimidine agent S-1 induced interstitial lung disease:A case report

作     者：Hiromichi Yamane Masahide Kinugawa Shigeki Umemura Yasuhiro Shiote Kenichiro Kudo Toshimitsu Suwaki Haruhito Kamei Nagio Takigawa Katsuyuki Kiura 

作者机构：Division of Clinical OncologySumitomo-Besshi Hospital Cancer Center3-1 Ohji-choNiihamaEhime 792-8543Japan 4th Department of General MedicineKawasaki Medical School2-1-80 NakasangeOkayama 700-8505Japan Department of Respiratory MedicineOkayama University Hospital2-5-1 Shikata-choOkayamaOkayama 700-8558Japan 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2011年第2卷第7期

页      面：299-302页

学科分类：10[医学] 

主　　题：Corticosteroid therapy Interstitial lung disease Pancreatic cancer S-1 

摘      要：A 66-year-old Japanese man with pancreatic cancer received eleven courses of gemcitabine *** tumor responded to gemcitabine until metastatic liver tumors ***,he was treated with S-1,an oral fluoropyrimidine anticancer agent,as salvage ***-two days after initiating S-1,he presented with dyspnea and *** computed tomography showed diffuse interstitial lesions with thickening of the alveolar septa and ground glass *** KL-6 level was elevated to 1,230 U/mL and he did not use any other drugs except ***,the development of interstitial lung disease(ILD)was considered to be due to *** blood oxygen pressure was 49.6 Torr in spite of oxygen administration(5 L/min).Steroid therapy improved his symptoms and the interstitial shadows on chest *** S-1-induced ILD has mostly been reported to be mild,clinicians should be aware that S-1 has the potential to cause fatal ILD.